Clinical Trials Directory

Trials / Unknown

UnknownNCT04391829

Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Universitair Ziekenhuis Brussel · Academic / Other
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

The objectives of the study, are to describe detection of SARS-CoV-2 in the semen of COVID-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

Detailed description

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a novel coronavirus reported in late December 2019 in Wuhan, China, has spread world-wide with over 1,000,000 coronavirus disease 2019 (COVID-19) cases reported. New developments in molecular virology and immunobiology of SARS-CoV-2, improve our understanding about COVID-19 prevention, management, and possible long-term effects. Although viral transmission occurs predominantly through respiratory droplets, SARS-CoV-2 has been isolated in blood samples and feces from COVID-19 patients, raising questions about viral shedding in other bodily fluids, including semen, as well as alternative modes of transmission. The objectives are to describe detection of SARS-CoV-2 in the semen of COVID-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEjaculated semen sampleSARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.

Timeline

Start date
2020-08-31
Primary completion
2021-08-31
Completion
2021-08-31
First posted
2020-05-18
Last updated
2020-10-28

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT04391829. Inclusion in this directory is not an endorsement.